89Zr uptake in bone (sternum, femur and knee) in HER2− tumour-bearing mice was comparable to that in HER2+ tumour-bearing mice: in both groups bone uptake was significantly lower in mice injected with [89Zr]Zr-DFOcyclo*-trastuzumab. This evidence concerns the gene ERBB2 and neoplasm.